Fig. 3

Nomogram prediction model for the risk of not achieving LDL-C reduction targets after using PCSK9 inhibitors. DBP, diastolic blood pressure; ALT, alanine aminotransferase; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; NTR-LDLC, nonattainment of target LDL-C reduction